2025年3月最新中科院分区数据已更新,欢迎查询使用。如果您对期刊系统有任何需求或者问题,欢迎
反馈给我们。近期推荐: | 热 SCI论文AI润色+人工QC服务 | 热 赛默飞基础学科研究有奖问卷 | 热 同行专家帮助选刊 | 热 Springer Nature特刊征稿 |
![]() |
基本信息 | 登录收藏 | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名字![]() | JOURNAL OF CLINICAL ONCOLOGY J CLIN ONCOL (此期刊被最新的JCR期刊SCIE收录) LetPub评分 9.9
53人评分
我要评分
声誉 9.9 影响力 9.9 速度 9.1 | |||||||||||||||||||||
期刊ISSN | 0732-183X | 微信扫码收藏此期刊 | ||||||||||||||||||||
E-ISSN | 1527-7755 | |||||||||||||||||||||
2023-2024最新影响因子 (数据来源于搜索引擎) | 42.1 点击查看影响因子趋势图 | |||||||||||||||||||||
实时影响因子 | 截止2025年5月19日:39.19 | |||||||||||||||||||||
2023-2024自引率 | 2.40%点击查看自引率趋势图 | |||||||||||||||||||||
五年影响因子 | 37.4 | |||||||||||||||||||||
JCI期刊引文指标 | 6.51 | |||||||||||||||||||||
h-index | 494 | |||||||||||||||||||||
CiteScore ( 2024年最新版) |
| |||||||||||||||||||||
期刊简介 |
| |||||||||||||||||||||
期刊官方网站 | http://jco.ascopubs.org/ | |||||||||||||||||||||
期刊投稿格式模板 VIP专享 |
| |||||||||||||||||||||
期刊投稿网址 | https://www.editorialmanager.com/JCO-ASCOPUBS | |||||||||||||||||||||
期刊语言要求 | 经LetPub语言功底雄厚的美籍native English speaker精心编辑的稿件,不仅能满足JOURNAL OF CLINICAL ONCOLOGY的语言要求,还能让JOURNAL OF CLINICAL ONCOLOGY编辑和审稿人得到更好的审稿体验,让稿件最大限度地被JOURNAL OF CLINICAL ONCOLOGY编辑和审稿人充分理解和公正评估。LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)帮助作者准备稿件,已助力全球15万+作者顺利发表论文。部分发表范例可查看:服务好评 论文致谢 。
提交文稿 | |||||||||||||||||||||
是否OA开放访问 | No | |||||||||||||||||||||
通讯方式 | AMER SOC CLINICAL ONCOLOGY, 2318 MILL ROAD, STE 800, ALEXANDRIA, USA, VA, 22314 | |||||||||||||||||||||
出版商 | American Society of Clinical Oncology | |||||||||||||||||||||
涉及的研究方向 | 医学-肿瘤学 | |||||||||||||||||||||
出版国家或地区 | UNITED STATES | |||||||||||||||||||||
出版语言 | English | |||||||||||||||||||||
出版周期 | Biweekly | |||||||||||||||||||||
出版年份 | 1983 | |||||||||||||||||||||
年文章数 | 479点击查看年文章数趋势图 | |||||||||||||||||||||
Gold OA文章占比 | 29.70% | |||||||||||||||||||||
研究类文章占比: 文章 ÷(文章 + 综述) | 96.87% | |||||||||||||||||||||
WOS期刊SCI分区 ( 2023-2024年最新版) | WOS分区等级:1区
| |||||||||||||||||||||
中国科学院《国际期刊预警 名单(试行)》名单 | 2025年03月发布的2025版:不在预警名单中 2024年02月发布的2024版:不在预警名单中 2023年01月发布的2023版:不在预警名单中 2021年12月发布的2021版:不在预警名单中 2020年12月发布的2020版:不在预警名单中 | |||||||||||||||||||||
中国科学院SCI期刊分区 ( 2025年3月最新升级版) | 点击查看中国科学院SCI期刊分区趋势图
| |||||||||||||||||||||
中国科学院SCI期刊分区 ( 2023年12月升级版) |
| |||||||||||||||||||||
中国科学院SCI期刊分区 ( 2022年12月旧的升级版) |
| |||||||||||||||||||||
SCI期刊收录coverage | Science Citation Index Expanded (SCIE) (2020年1月,原SCI撤销合并入SCIE,统称SCIE) Scopus (CiteScore) | |||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=0732-183X%5BISSN%5D | |||||||||||||||||||||
平均审稿速度 | 网友分享经验: 平均2月 | |||||||||||||||||||||
平均录用比例 | 网友分享经验: 约20% | |||||||||||||||||||||
LetPub助力发表 | 经LetPub编辑的稿件平均录用比例是未经润色的稿件的1.5倍,平均审稿时间缩短40%。众多作者在使用LetPub的专业SCI论文编辑服务(包括SCI论文英语润色,同行资深专家修改润色,SCI论文专业翻译,SCI论文格式排版,专业学术制图等)后论文在JOURNAL OF CLINICAL ONCOLOGY顺利发表。
快看看作者怎么说吧:服务好评 论文致谢 。 提交文稿 | |||||||||||||||||||||
期刊常用信息链接 |
|
|
|
|
中国学者近期发表的论文 | |
1. | Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer Author: Awad, Mark M.; Forde, Patrick M.; Girard, Nicolas; Spicer, Jonathan; Wang, Changli; Lu, Shun; Mitsudomi, Tetsuya; Felip, Enriqueta; Broderick, Stephen R.; Swanson, Scott J.; Brahmer, Julie; Kerr, Keith; Saylors, Gene B.; Chen, Ke-Neng; Gharpure, Vishwanath; Neely, Jaclyn; Balli, David; Hu, Nan; Pulla, Mariano Provencio Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 12, pp. -. DOI: 10.1200/JCO-24-02239 PubMed DOI |
2. | Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: The Phase III MECCA Trial Author: Hong, Ruo-Xi; Xu, Fei; Xia, Wen; Teng, Yue-E; Ouyang, Qu-Chang; Zheng, Qiu-Fan; Yuan, Zhong-Yu; Chen, Dong-Shao; Jiang, Kui-Kui; Lin, Ying; Dai, Zhen; Liu, Xin-Lan; Chen, Qian-Jun; Wu, Xin-Hong; Shi, Yan-Xia; Huang, Jia-Jia; An, Xin; Xue, Cong; Bi, Xi-Wen; Chen, Mei-Ting; Li, Hui; Yao, He-Rui; Zou, Guo-Rong; Huang, Heng; Zhang, Jing-Min; Wang, Shu-Sen Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 11, pp. -. DOI: 10.1200/JCO.24.00938 PubMed DOI |
3. | HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study Author: Heymach, John V.; Opdam, Frans; Barve, Minal; Tu, Hai-Yan; Wu, Yi-Long; Berz, David; Schroeter, Lukas; Botilde, Yanick; Sadrolhefazi, Behbood; Serra, Josep; Yoh, Kiyotaka; Yamamoto, Noboru Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 11, pp. -. DOI: 10.1200/JCO-24-01727 PubMed DOI |
4. | Concerns on Potential Risk of Roxadustat in Promoting Tumor Progression: Double-Edged Sword of Hypoxia-Inducible Factor-1α Activation Author: Tan, Jing; Chen, Lin; Zhu, Rui Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 10, pp. -. DOI: 10.1200/JCO-24-02305 PubMed DOI |
5. | Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal Tumors Author: Mascarenhas, Leo; Dubois, Steven G.; Albert, Catherine M.; Bielack, Stefan; Orbach, Daniel; Federman, Noah; Geoerger, Birgit; Nagasubramanian, Ramamoorthy; Zhang, Yizhou; Chisholm, Julia; Melcon, Soledad Gallego; Goto, Hiroaki; Morgenstern, Daniel A.; Owens, Cormac; Pappo, Alberto S.; Perreault, Sebastien; Schulte, Johannes H.; Shukla, Neerav; Zwaan, Christian Michel; Neu, Natascha; Bernard-Gauthier, Vadim; de la Cuesta, Esther; van Tilburg, Cornelis M.; Laetsch, Theodore W. Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 10, pp. -. DOI: 10.1200/JCO.24.00848 PubMed DOI |
6. | Reply to: Concerns on Potential Risk of Roxadustat in Promoting Tumor Progression: Double-Edged Sword of Hypoxia-Inducible Factor-1α Activation Author: Lu, Shun; Wu, Jiong Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 10, pp. -. DOI: 10.1200/JCO-24-02684 PubMed DOI |
7. | Global spatiotemporal trends in prostate cancer burden and its socioeconomic disparities: An observational study from 1990 to 2021. Author: Zhou, Xianghong; Wei, Qiang Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 5_SUPPL, pp. 325-325. DOI: 10.1200/JCO.2025.43.5_suppl.325 DOI |
8. | Circulating tumor DNA (ctDNA) monitoring in the assessment and prediction of the efficacy of PARP inhibitors (PARPi). Author: Zhao, Diwei; Zhao, Junliang; Li, Yuanwei; Cai, Xinyang; Yang, Zhenyu; Zhou, Fangjian; Li, Yonghong; Wang, Jun Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 5_SUPPL, pp. TPS307-TPS307. DOI: 10.1200/JCO.2025.43.5_suppl.TPS307 DOI |
9. | An online clustering algorithm predicting model for prostate cancer based on PHI-related variables and PI-RADS in different PSA populations. Author: Zhang, Gejun; Hu, Jiyuan Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 5_SUPPL, pp. 328-328. DOI: 10.1200/JCO.2025.43.5_suppl.328 DOI |
10. | Optimizing the strategies to perform prostate biopsy in MRI-positive patients: A systematic review and network meta-analysis. Author: Wu, Qiyou; Tu, Xiang; Tang, Bo; Bao, Yige; Wei, Qiang Journal: JOURNAL OF CLINICAL ONCOLOGY. 2025; Vol. 43, Issue 5_SUPPL, pp. 340-340. DOI: 10.1200/JCO.2025.43.5_suppl.340 DOI |
|
|
|
联系我们 | 站点地图 | 友情链接 | 授权代理商 | 加入我们
© 2010-2025 中国: LetPub上海 网站备案号:沪ICP备10217908号-1 沪公网安备号:31010402006960 (网站)31010405000484 (蝌蝌APP)
增值电信业务经营许可证:沪B2-20211595 网络文化经营许可证:沪网文[2023]2004-152号
礼翰商务信息咨询(上海)有限公司 办公地址:上海市徐汇区漕溪北路88号圣爱大厦1803室